title: Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
abstract: OBJECTIVE
  To assess endocrine differences during early luteal phase according to mode of triggering final oocyte maturation with or without luteal phase support (LPS).
  
  
  METHODS
  A prospective randomized study.
  
  
  METHODS
  University center for reproductive medicine.
  
  
  METHODS
  Four oocyte donors each underwent four consecutive cycles.
  
  
  METHODS
  To avoid interpatient variation, each donor underwent the same stimulation regimen. However, different modes of triggering final oocyte maturation and LPS were administered: A) 10,000 IU hCG and standard LPS; B) GnRH agonist (GnRHa; 0.2 mg triptorelin), and 35 hours later 1,500 IU hCG, and standard LPS; C) GnRH agonist (0.2 mg triptorelin) and standard LPS; and D) GnRH agonist (0.2 mg triptorelin) without LPS.
  
  
  METHODS
  Blood sampling was performed on the day of ovulation trigger, ovulation trigger + 1 day, and ovum pick-up + 5 days. Serum E2, FSH, LH, and P were measured.
  
  
  RESULTS
  The early luteal phase steroid levels following GnRHa trigger and modified luteal phase support (B) were similar to those seen after hCG trigger (A). However, significant differences were seen between groups A and B compared with C and D, as well as between groups C and D.
  
  
  CONCLUSIONS
  Administration of a single bolus of GnRHa effectively induced LH and FSH surges in oocyte donors stimulated with recombinant FSH and cotreated with a GnRH antagonist. However, gonadotropin and steroid levels differed significantly according to the type of luteal phase support used after GnRHa trigger.
  2009-009429-26.
authors.affiliation: Center for Reproductive Medicine, Dutch-Speaking Free University, Brussels, Belgium. hmousavi@uzbrussel.be
authors.forename: Human M
authors.initials: HM
authors.lastname: Fatemi
authors.forename: Nikolaos P
authors.initials: NP
authors.lastname: Polyzos
authors.forename: Inge
authors.initials: I
authors.lastname: van Vaerenbergh
authors.forename: Claire
authors.initials: C
authors.lastname: Bourgain
authors.forename: Christophe
authors.initials: C
authors.lastname: Blockeel
authors.forename: Birgit
authors.initials: B
authors.lastname: Alsbjerg
authors.forename: Evangelos G
authors.initials: EG
authors.lastname: Papanikolaou
authors.forename: Peter
authors.initials: P
authors.lastname: Humaidan
mesh_terms: D000328:Adult; D004958:Estradiol / Q000097:blood; D005260:Female; D005300:Fertility Agents, Female / Q000494:pharmacology / Q000627:therapeutic use; D005307:Fertilization in Vitro / Q000379:methods*; D005640:Follicle Stimulating Hormone / Q000037:antagonists & inhibitors / Q000097:blood; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors; D006727:Hormone Antagonists / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D008183:Luteal Phase / Q000097:blood* / Q000187:drug effects*; D007986:Luteinizing Hormone / Q000097:blood; D009865:Oocytes / Q000187:drug effects / Q000502:physiology; D009866:Oogenesis / Q000187:drug effects / Q000502:physiology; D010062:Ovulation Induction / Q000379:methods*; D011247:Pregnancy; D011374:Progesterone / Q000097:blood; D013997:Time Factors; D017329:Triptorelin Pamoate / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D005300:Fertility Agents, Female; D006727:Hormone Antagonists; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone
keywords: GnRH agonist trigger; GnRH antagonist; Progesterone; hCG; luteal phase